4D Molecular Therapeutics
4D Molecular Therapeutics is a late-stage biotechnology company that uses its Therapeutic Vector Evolution platform to design, develop and commercialize customized gene delivery vectors for serious unmet medical conditions.
Last updated September 26, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
4D Molecular Therapeutics (often abbreviated 4DMT) is a biotechnology company focused on genetic medicines. According to its official website, the company "designs, develops and commercializes transformative gene therapeutic products for serious unmet medical conditions." Its work sits at the intersection of gene therapy, vector engineering and product development, with the goal of creating treatments that are durable, disease-targeted and potentially curative. The company describes itself as "a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients." Its central technology is a vector discovery platform called Therapeutic Vector Evolution. Through this platform, 4DMT creates customized and proprietary gene delivery vehicles — vectors — intended to deliver therapeutic payloads to specific tissue types associated with the underlying disease, using what the company considers the optimal route of administration. Rather than relying solely on naturally occurring or conventional vectors, 4DMT's approach is to evolve vectors with desired properties, then pair them with therapeutic payloads and manufacturing processes. The company states that its "product design, development and manufacturing engine" allows it to efficiently create a diverse product pipeline. This combination of vector discovery, payload design and manufacturing capability is presented as the foundation of its strategy to "revolutionize genetic medicines and to strive for potential curative therapies." 4D Molecular Therapeutics is based in the United States and operates primarily in the U.S. biotech market, though specific details such as its headquarters city, founding year, founders, ownership structure and stock listing are not established by the supplied evidence. Its public identity is that of a clinical- and late-stage-focused genetic medicines company whose brand is closely tied to its Therapeutic Vector Evolution platform and its pipeline of customized gene therapies.
History
4D Molecular Therapeutics is a U.S.-based biotechnology company dedicated to genetic medicines. Its public narrative centers on the development of customized gene delivery vectors and therapeutic products for serious unmet medical conditions. The company describes itself as "a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients." The foundation of the company's approach is its vector discovery platform, Therapeutic Vector Evolution. This platform is used to create customized and proprietary gene delivery vehicles — vectors — that are designed to deliver therapeutic payloads to specific tissue types associated with the underlying disease via the optimal route of administration. By evolving vectors rather than relying only on naturally occurring ones, 4DMT aims to improve targeting, durability and clinical potential. Beyond vector discovery, the company emphasizes an integrated "product design, development and manufacturing engine." This engine is intended to allow 4DMT to efficiently create a valuable and diverse product pipeline. The combination of vector engineering, payload design and manufacturing capability forms the core of the company's strategy to "revolutionize genetic medicines and to strive for potential curative therapies." Specific historical details — such as the exact founding year, founders, headquarters location, financing rounds, partnerships, clinical milestones and stock listing — are not established by the supplied evidence. The available official materials present 4DMT as an active, late-stage biotechnology company whose identity and brand are closely tied to its Therapeutic Vector Evolution platform and its pipeline of customized gene therapies.
Products and positioning
A late-stage biotechnology company advancing durable, disease-targeted genetic medicines through its proprietary Therapeutic Vector Evolution vector discovery platform.
Therapeutic Vector Evolution platform
A transformative vector discovery platform used to create customized and proprietary gene delivery vehicles (vectors) that deliver therapeutic payloads to specific tissue types via the optimal route of administration.
Customized gene delivery vectors
Proprietary vectors engineered through Therapeutic Vector Evolution to target specific tissues associated with disease.
Gene therapeutic products
Transformative gene therapeutic products designed, developed and commercialized for serious unmet medical conditions.
Recent events
Roche terminates collaboration and license agreement with 4DMT[4]
Reported:
4D Molecular Therapeutics announced that Roche terminated their collaboration and license agreement covering certain rights to 4D-110; 4DMT said it would regain full rights to the candidate as a result.
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/4d-molecular-therapeutics · Editorial policy · How profiles are compiled